T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Clinical trial NCT04457596 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04457596
Sponsor: Alliance for Clinical Trials in Oncology
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 HER2 Positive Breast Carcinoma Invasive Breast Carcinoma Multifocal Breast Carcinoma Synchronous Bilateral Breast Carcinoma Anatomic Stage I Breast Cancer AJCC v8

Start date: 2021-03-02
Primary completion: 2028-01-31
Enrollment: 1056

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.